Concretely: early satiety · liraglutide.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Why does this happen, and what would falsify the usual explanation?
The relevant detail is that diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
| Event | Active arm | Placebo arm | Timing |
|---|---|---|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Symptoms appearing late at a stable dose deserve a differential diagnosis rather than an assumption.
Smaller meals, less fat, fluids between rather than with. In that order.
edited 16 Nov 2025 by Dr_Marek_Zielinski — added the method parameters
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the titration history, because going faster than the schedule is the single largest modifiable factor.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.
Research-use compounds are not approved for human use.
Most people who report these effects continue. The discontinuation rate is low.
edited 16 Dec 2025 by Dr_Nadia_Farsi — reworded for clarity after a comment
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.